Introduction
Children with congenital heart disease (CHD) and abnormal pulmonary haemodynamics are at risk for developing pulmonary arterial hypertension (PAH). [1] [2] [3] This progressive disease is characterized by a typical remodelling of small pulmonary arterioles, leading to increased pulmonary vascular resistance (PVR), but also by remodelling of the larger pulmonary conduit arteries, resulting in increased pulmonary arterial (PA) stiffness. 4, 5 Both contribute to the increased right ventricular (RV) afterload in PAH that ultimately leads to RV failure and death. 6 In children with CHD, increased pulmonary blood flow due to systemic-to-pulmonary shunting induces early changes in the pulmonary vasculature that precede the development of advanced PAH, which include endothelial dysfunction and vascular smooth muscle cell proliferation. [7] [8] [9] [10] [11] The continuum from these early pulmonary vascular changes to advanced PAH is referred to as pulmonary vascular disease (PVD). PVR and mean PA pressure (mPAP) are important haemodynamic measurements in the evaluation of PVD and are used to define PAH and guide therapy decisions such as whether and when a cardiac defect should be repaired or when PAH-targeted therapy should be initiated. [12] [13] [14] [15] However, in the early disease stage, these measurements lack sensitivity in predicting either advancing or reversibility of disease. [16] [17] [18] Alterations in pulsatile flow due to PA stiffening have substantial effects on RV-afterload but are not taken into account in these conventional haemodynamic measurements that assume steady flow. [19] [20] [21] Assessment of pulsatile characteristics of the pulmonary vasculature such as PA-stiffness may aid haemodynamic evaluation of PVD and RV-afterload. 22 It has been suggested that concomitant measurement of PA stiffness indices could allow for more accurate prediction of advanced PAH at long-term follow-up, adverse implications of shunt closure and mortality, especially in the early stage of the disease. 10, 23, 24 To explore this, the current long-term follow-up study aims to correlate PA stiffness indices with late outcome, defined as advanced PAH as well as mortality during follow-up, in children with early CHD-associated arterial PVD.
Methods

Study design and population
Between April 1994 and July 1997, 47 consecutive young patients with CHD-associated PVD were prospectively enrolled in a study to investigate the clinical value of pulsatile PA-characteristics obtained by intravascular ultrasound (IVUS) in the assessment of PVD. 25, 26 Patients were <20 years of age and PVD was confirmed with right heart catheterization. At that time, PVD was defined as increased PA pressure (mPAP > _ 20 mmHg) and/or increased pulmonary blood flow (pulmonary-to-systemic blood flow ratio [Qp/Qs] > _1.2). The originally used inclusion cutoff value of 20 mmHg for mPAP thus implies the inclusion of patients with mPAP between 20 and 25 mmHg, who according to recent guidelines are to be carefully followed especially in populations at risk for developing PAH. 13, 14 It has been demonstrated that increased pulmonary flow leads to endothelial dysfunction and muscularization of pulmonary arterioles that are normally non-muscularized, which is the start of plexogenic arteriopathy in PVD. [7] [8] [9] As the current study focuses on the development of advanced PAH over time, six patients with PVD due to pulmonary venous congestion, defined as mean pulmonary capillary wedge pressure (mPCWP) > _15 mmHg, that were included in the original cohort, were excluded for this study. The remaining 41 patients were followed in two centres in the Netherlands. Ethical approval for this study was obtained from the institutional review boards and subjects and/or their guardians provided written informed consent at enrolment.
In order to stratify for baseline haemodynamics, patients were categorized into four haemodynamic baseline profiles: (A) Early non-flow related PVD, defined as mPAP [20] [21] [22] [23] [24] [25] 12-14 Conventional haemodynamics of profiles A, B, and C were together referred to as 'favourable' and those of group D as 'unfavourable' according to recent guidelines. 13 
Cardiac catheterization and IVUS-imaging
Details regarding haemodynamic evaluation and IVUS-imaging have been reported previously. 25, 26 In short, complete haemodynamic evaluation was performed in one centre by cardiac catheterization according to a predefined protocol. In this catheterization procedure, IVUS-imaging of pulmonary arteries was performed following haemodynamic measurements, using a Sonos Intravascular Imaging-System (Hewlett Packard, Andover, MA, USA) and a Sonicath 3.5F or Spy 3.0F ultrasound catheter with a 30-MHz transducer at the tip (Boston Scientific, Watertown, MA, USA). The ultrasound catheter was directed through a 6F sheath along the pulmonary branch at consecutive sites in proximal, segmental, and peripheral arteries. For the current follow-up study, each most proximally obtained measurement was used for analysis. PA luminal area was measured offline at end-diastolic and peak-systolic dimension, with averaging over three cardiac cycles and over two independent observers. PA relative area change (PA-RAC), reflecting the relative change in arterial cross-sectional area (sometimes also referred to as 'pulsatility'), was calculated as (peak-systolic -end-diastolic luminal area)/ (end-diastolic area). PA-stiffness was characterized by calculating the indices PA cross-sectional area compliance (PA-compliance) and PA crosssectional area distensibility (PA-distensibility), which can be regarded as the conceptual inverse of stiffness. 21, 27 PA-compliance is the absolute change in PA cross-sectional area for a given pressure change and was calculated as: (peak systolic -end-diastolic luminal area)/PA pulse pressure. PA-distensibility is the relative change in PA cross-sectional area for a given pressure change and was calculated as: (PA-RAC/PA pulsepressure)*100%.
Long-term outcome
After baseline haemodynamic evaluation and IVUS-imaging, patients were treated at distinction of the treating physician. Treatment could include either surgical or interventional closure of a systemic-to-pulmonary shunt, or treatment for advanced PAH, the latter having evolved over time in accordance with the available treatment strategies and guidelines. [28] [29] [30] [31] [32] All patients were followed long-term at two centres, until 1 March 2015. Outcome parameters were defined as advanced PAH and mortality at long-term follow-up.
(1) Advanced PAH at long-term follow-up. During follow-up, serial transthoracic echocardiography was performed as part of routine clinical practice. Follow-up echocardiography reports were scrutinized to determine whether there was advanced PAH. Evidence of PAH at long-term follow-up was defined as either (1) the presence of pulmonary-to-systemic shunting or (2) maximum systolic tricuspid regurgitant velocity >2.8 m/s accompanied by one or more of the following signs of RV overload: moderate to severe RV hypertrophy or dilatation, septal flattening or pericardial effusion. 33 Follow-up 
Data analysis
Data are presented as median (interquartile range) or frequencies (percentage). Statistical analysis was performed using IBM-SPSS 22.0. In the regression analyses, logarithmic transformation was used to normalize the distribution of variables that were not normally distributed. All statistical tests were two-sided and P-values < 0.05 were considered statistically significant. Continuous variables were compared using Mann-Whitney U test or Kruskal-Wallis test. Geometric means were compared by conducting unpaired t-tests of logarithmically transformed variables. Categorical variables were compared using Fisher's exact test. Binary logistic regression analysis was used to evaluate the association of PA-stiffness indices with long-term PVD status, defined as either reversed PVD or advanced PAH at long-term follow-up, as established at last follow-up. Cox regression analysis was used to evaluate the association of PA-stiffness indices with PVD-related mortality. The follow-up time was calculated from the IVUS-study until 1 March 2015 or until date of death when applicable. In the logistic and Cox regression models, statistically significant variables were adjusted for age, sex, and vessel size using the PA cross-sectional end-diastolic luminal area. Further multivariable analysis of conventional variables was considered inappropriate in view of the sample size. In addition, the effect sizes were compared between patients with favourable (Profile A, B, or C) and unfavourable (Profile D) haemodynamic profiles at baseline by testing the interaction of favourable haemodynamics with significant variables.
Receiver-operating-characteristic (ROC) analysis was performed to determine the most optimal threshold value of baseline PA-compliance, PA-distensibility, and PVRi to distinguish between reversed PVD and advanced PAH at long-term follow-up. Kaplan-Meier analysis was used to visualize survival of patients above and below the identified threshold values. Survival differences were compared by means of a log-rank test.
Results
Baseline characteristics
Forty-one children with arterial PVD were followed during a median (interquartile range) time of 19 (18) (19) (20) years. Median (interquartile range) age at time of the IVUS-study was 2.1 (0.6-6.4) years. The profiling according to haemodynamics at baseline is shown in the upper section of Figure 1 . Table 1 shows the clinical characteristics, stratified by haemodynamic baseline profiles. Inherent to the categorization based on haemodynamics, the profiles differed significantly with regards to haemodynamic variables. In addition, PA-RAC (P = 0.026) and PA-distensibility (P = 0.003) varied significantly according to the profiles. Details regarding congenital heart defect status at baseline are provided as Supplementary data online, Table S1 .
Long-term outcome
All patients were available for follow-up. Following cardiac catheterization at baseline, 27 (66%) patients underwent shunt closure.
1. Advanced PAH at long-term follow-up. During follow-up, in 31 (76%) cases PVD had reversed and in 10 (24%) cases there was advanced PAH (Figure 1) . Of the latter, 3/10 had Eisenmenger physiology. In addition to repeated echocardiographic confirmation of PAH (TR Vmax range: 3.8-6.0 m/s), advanced PAH was confirmed with follow-up cardiac catheterizations in 8/10 cases (mPAP range: 31-91 mmHg, the two patients without follow-up cardiac catheterization had Eisenmenger physiology). 6/10 received PAH-targeted therapies, when these became available during follow-up. None of the patients with advanced PAH at follow-up had undergone shunt closure after IVUS-imaging. From the subgroup of patients with favourable haemodynamics at baseline (Profile A þ BþC), advanced PAH developed in 3 out of 27 patients (11%) during follow-up.
In the total cohort, patients with advanced PAH at follow-up had less favourable conventional haemodynamics at baseline and also lower PA-compliance and PA-distensibility ( Table 2) . Patients with advanced PAH at follow-up had significantly lower geometric means of PA-compliance and PA-distensibility and significantly higher PVRi at baseline compared with those with reversed PVD (Figure 2) and this remained the case within the subgroup of patients with favourable haemodynamics at baseline (Profile A þ BþC). Logistic regression analysis confirmed that lower baseline PA-compliance and PAdistensibility correlated significantly with advanced PAH at long-term follow-up (P = 0.007 and P = 0.009), as did higher PVRi (P = 0.002), also after adjusting for age, sex, and PA end-diastolic luminal area ( Table 3) . The interaction analysis showed that these identified associations did not differ between patients with favourable or unfavourable haemodynamic profiles. PA-RAC did not correlate with advanced PAH at follow-up (P = 0.324) ROC analysis yielded area's under the curve for PA-compliance, PA-distensibility, and PVRi of 0.83, 0.83, and 0.95, respectively, which did not differ significantly from each other. Optimal cut-off values to distinguish between reversed PVD and advanced PAH were 0.08 mm Data are presented as median (interquartile range) or number (percentage), unless otherwise indicated. BSA, body surface area; EDA, end-diastolic cross-sectional pulmonary arterial luminal area; ESA, end-systolic cross-sectional pulmonary arterial luminal area; IVUS, intravascular ultrasound; mPAP, mean pulmonary artery pressure; mPCWP, mean pulmonary capillary wedge pressure; PA-RAC, pulmonary arterial relative area change; PA-Compl., pulmonary arterial area compliance; PA-Dist., pulmonary arterial area distensibility; PAH, pulmonary arterial hypertension; PVD, pulmonary vascular disease; PVRi, indexed pulmonary vascular resistance; Qp/Qs, pulmonary-to-systemic flow ratio; Qsi, systemic flow index. provides patient-level plots of PA-compliance, PA-distensibility, and PVRi stratified by long-term PVD-status, in reference to these cutoffs. All three patients who developed advanced PAH at follow-up had baseline PA-compliance and PA-distensibility values that were below the identified cut-off values (note that direction of PAcompliance/PA-distensibility is reversed in Figure 3 ). 2. Mortality. During follow-up, death occurred in seven (17%) patients, of which six were regarded PVD related. Causes of death were sudden death (n = 2), progressive RV-failure (n = 2), and massive haemoptysis (n = 2). One patient died as a consequence of severe neurological complications due to Trisomy-18, considered unrelated to PVD. In the analyses, this patient was regarded a survivor, with censoring from the time of death. There were no patients who underwent heart or lung transplantation.
Cox regression analysis showed that lower PA-compliance and PA-distensibility correlated significantly with mortality (P = 0.018 and P = 0.013), as did higher PVRi (P = 0.005), also after adjusting for age, sex, and end-diastolic luminal area ( Table 3) . The interaction analysis showed that these identified associations did not differ significantly between patients with favourable or unfavourable haemodynamic profiles. PA-RAC did not correlate with mortality (P = 0.204). Figure 4 shows survival of PVD patients with values of PA-compliance, PA-distensibility, and PVRi above vs. below the respective identified cut-off values. Patients with PA-compliance < _0.08 mm/mmHg, PA-distensibility < _0.95%/mmHg, or PVRi > _4 WU*m 2 showed significantly worse survival (log-rank P = 0.011, P = 0.009, and P < 0.001, respectively).
Discussion
This long-term follow-up study in a series of young patients with PVD demonstrates that both PA-stiffness indices and PVRi predict advanced PAH and mortality. In a subgroup of patients with favourable haemodynamics at baseline, 11% progressed to advanced PAH during follow-up. In these patients, PA-stiffness indices showed to be highly sensitive regarding the prediction of future PVD progression. Based on data from the current cohort, our group previously demonstrated that IVUS-derived PA stiffness indices differ significantly between cases and controls, independently of PA-pressure, and correlate with disease severity in children with PVD. 26 Data are presented as median (interquartile range) or number (percentage), unless otherwise indicated. BSA, body surface area; EDA, end-diastolic cross-sectional pulmonary arterial luminal area; ESA, end-systolic cross-sectional pulmonary arterial luminal area; IVUS, intravascular ultrasound; mPAP, mean pulmonary artery pressure; mPCWP, mean pulmonary capillary wedge pressure; PA-RAC, pulmonary arterial relative area change; PA-Compl., pulmonary arterial area compliance; PA-Dist., pulmonary arterial area distensibility; PAH, pulmonary arterial hypertension; PVD, pulmonary vascular disease; PVRi, indexed pulmonary vascular resistance; Qp/Qs, pulmonary to systemic flow ratio; Qsi, systemic flow index.
. ; however, the current data do not support this. PA-RAC reflects the relative change in PA luminal area not taking into account the accompanying pressure change and is thus not a measure of intrinsic wall properties. Although its potential for non-invasive measurement may be clinically appealing, to assess arterial wall properties in a viscoelastic pulmonary artery, the systolic-diastolic area should be adjusted for pulse pressure. Relative changes of luminal area are PVR is a cornerstone in the clinical diagnosis of PVD and the prognostication of disease progression and mortality, especially in the advanced stages of PAH. [12] [13] 37, 38 Indeed, the results of the current study confirm the well-recognized prognostic value of an increased PVR and show that in the studied children an optimal cut-off value for predicting advanced PAH or mortality at long-term follow-up was > _ 4 WU*m 2 . This observation is in line with the current PVRbased recommendations for correction of CHD in the presence of PAH. 13 However, an important result from the current study is that patients with favourable haemodynamic baseline profiles may still Log unit increase. CI, confidence interval; EDA, end diastolic cross-sectional pulmonary arterial luminal area; HR, hazard ratio; PA-RAC, pulmonary arterial relative area change; PA-Compl., pulmonary arterial area compliance; PA-Dist., pulmonary arterial area distensibility; PVD, pulmonary vascular disease; PVRi, indexed pulmonary vascular resistance. a Favourable/unfavourable hemodynamics interaction analysis: P < 0.05 would indicate a significant effect size difference between patients with favourable and unfavourable haemodynamic profiles at baseline. measures of PA-stiffness indices showed to carry prognostic value regarding progression to advanced PAH and outcome. Especially in this setting of early PVD stages, characterized by favourable conventional haemodynamics with relatively low PVR, PA stiffness measurements may proof of particular benefit and provide added value to conventional haemodynamics. In the current study, this was evidenced by the observation that all patients whose PVD progressed to advanced PAH during follow-up despite favourable haemodynamics at baseline could be identified using PA-stiffness cut-off values, whereas this was not possible using a PVRi cut-off value of 4 WU*m 2 . Of note, conclusions regarding independence or superiority of PA stiffness indices over PVRi cannot be drawn from this study, as the sample size hampered extensive multivariable modelling.
Strengths and limitations
The current 20-year follow-up data of a cohort of children with various stages of CHD-associated PVD, meticulously characterized at diagnosis by both conventional pulmonary haemodynamics and PAstiffness indices, are unique and provide important information on the development of PVD over time in this population. Strengths of this study include the complete data without any loss to follow-up, the highly standardized and predefined protocol for haemodynamic assessment and IVUS-imaging and the near-simultaneous measurement of PA luminal area and pressure changes.
The sample size obviously limited the analyses. In the present cohort, there were no patients whose PVD did not reverse after correction of a cardiac shunt, which hampered conclusions regarding the role of PA-stiffness indices in predicting adverse effects of shunt closure. The cohort consisted of patients with different haemodynamic baseline profiles and associated types of CHD, with inherent heterogeneity. Important areas of future research are the evaluation of serial measurements over time and the development of interventions that specifically target PA-stiffness.
Conclusions
In children with PVD, PA-stiffness indices assessed by IVUS correlate with advanced PAH and mortality at long-term follow-up. Especially in patients with early stages of PVD with an assumed favourable haemodynamic profile, assessment of intrinsic PA-stiffness indices appears a valuable tool that may enhance the prognostication of disease progression and survival.
